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Abstract
Large, rare copy number variants (CNV) have been implicated in a variety of psychiatric 
disorders, but the role of CNVs in recurrent depression is unclear. We performed a genome-wide 
analysis of large, rare CNVs in 3,106 cases of recurrent depression, 459 controls screened for 
lifetime-absence of psychiatric disorder and 5,619 unscreened controls from phase 2 of the 
Wellcome Trust Case Control Consortium (WTCCC2). We compared the frequency of cases with 
CNVs against the frequency observed in each control group, analysing CNVs over the whole 
genome, genic, intergenic, intronic and exonic regions. We found that deletion CNVs were 
associated with recurrent depression while duplications were not. The effect was significant when 
comparing cases to WTCCC2 controls (p=7.7×10−6, OR =1.25 (95% CI 1.13 - 1.37)) and to 
screened controls (p=5.6×10−4, OR=1.52 (95% CI 1.20 - 1.93). Further analysis showed that 
CNVs deleting protein coding regions were largely responsible for the association. Within an 
analysis of regions previously implicated in schizophrenia, we found an overall enrichment of 
CNVs in our cases when compared to screened controls (p=0.019). We observe an ordered 
increase of samples with deletion CNVs, with the lowest proportion seen in screened controls, the 
next highest in unscreened controls and the highest in cases. This may suggest that the absence of 
deletion CNVs, especially in genes, is associated with resilience to recurrent depression.
INTRODUCTION
Recurrent depressive disorder is a common psychiatric disorder associated with high 
morbidity, high economic burden and high rates of completed suicide (1-3). Depressive 
disorder is heritable, with recurrent and severe types being substantially so (4, 5), but the 
specific genes involved are not known. Since recurrent depression is associated with 
increased mortality at a young age (3) it is logical to expect that some of the genetic 
contribution to the disorder may be explained by rare genomic variants operating under 
negative selection pressure (6).
Genome-wide association studies of single nucleotide polymorphisms have been 
inconsistent in depression (7, 8). However there is increasingly robust evidence that copy 
number variants (CNV), defined as submicroscopic deletions or duplications of genomic 
DNA seen at a frequency of less than 1 in 100 in the general population (9), are associated 
with a range of psychiatric disorders (10-16). A genome wide analysis of CNVs in recurrent 
depression has not yet been undertaken. Thus we decided to analyse Illumina microarray 
data for evidence of copy number variation in a large cohort of cases of recurrent depression 
and compare this to two control samples; one consisting of participants screened for a 
lifetime-absence of psychiatric disorder and another larger, unscreened population control 
cohort from phase 2 of the Wellcome Trust Case Control Consortium (WTCCC2).
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METHODS
SAMPLES
3,106 cases (2,188 female & 918 male) of depression were taken from two studies of 
recurrent depression and a pharmacogenetic study of antidepressant response. Details of 
these studies have been published elsewhere (17-19) and further details are also provided in 
the supplementary information. All studies were approved by local ethics committees and 
informed written consent was gained from all participants. All cases were ascertained by 
interview with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (20) and 
fulfilled criteria for depression of at least moderate severity (2 or more episodes) under 
ICD-10 or DSM IV criteria. Subjects were excluded if there was a history or family history 
of schizophrenia or bipolar disorder or if mood symptoms were secondary to alcohol or 
substance misuse. Subjects with mood congruent psychotic symptoms were not excluded.
459 controls (281 female & 178 male) comprehensively screened for a lifetime-absence of 
psychiatric disorder were recruited. Potential subjects for the screened control group were 
collected from students and staff at Kings College London by internal email advertisement 
and by local media advertisement. Subjects were interviewed with a modified version of the 
Past History Schedule (21) and were included only if they demonstrated no evidence of past 
or present psychiatric disorder. Subjects were also interviewed with the Beck Depression 
Inventory (22) and excluded if they scored more than 10.
As an additional control set we also used 5,619 control samples (2,611 female & 2,668 
male) from phase 2 of the Wellcome Trust Case Control Consortium (WTCCC2) composed 
of the 1958 British birth cohort and the national blood service cohort. The 1958 British birth 
cohort is a sample of sequential live births in the UK during one week in 1958, whilst the 
national blood service cohort is drawn from subjects who have donated blood to the UK 
blood services collection (further details can be found in the supplementary information).
Our control samples are of exclusively UK ethnic origin. However some of our case samples 
have non-UK, European heritage. Within our analyses we have attempted to account for this 
potential confounding factor by performing an additional analysis restricted to samples with 
exclusively UK origins.
GENOTYPING
All DNA samples were obtained from venous blood. We genotyped our case sample and 
screened control samples on the Illumina (San Diego, CA, USA) HumanHap 610-Quad 
Beadchip and all DNA samples were processed contemporaneously at the same laboratory 
with stringent quality control and full Laboratory Information Management Systems (LIMS) 
monitoring. Samples from the WTCCC2 cohort were genotyped on a modified Illumina 1M 
beadchip which is technically very similar to the 610-Quad beadchip. We were granted 
access to the chip intensity data (Illumina ‘.idat’ files). All probe intensity data was 
normalised and processed using standard Illumina protocols with Illumina’s GenomeStudio 
platform to obtain the log R ratio (LRR) and B allele frequency (BAF) at each marker. The 
LRR and BAF represent, for each marker in each sample, a summed probe intensity ratio 
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derived from comparison to a canonical value calculated from all samples, and, in the case 
of bi-allelic probes, an allelic intensity ratio, respectively.
CNV CALLING
All our calls and analysis are based on build 18 of the human genome reference sequence. 
We processed LRR and BAF values for autosomal markers in common to both Illumina 
arrays (n=562,680) using PennCNV (version released August 2009), a popular, open-source 
package designed for Illumina array data that implements a hidden Markov model, a Viterbi 
algorithm, expectation maximisation and takes account of the distance between consecutive 
markers to make copy number calls (23).
SAMPLE AND CNV QUALITY CONTROL
Samples with a genotype call rate of less than 98%, a B allele frequency standard deviation 
(BAFSD) of more than 0.045 or a log R ratio standard deviation (LRRSD) of more than 0.3 
were excluded from analysis. We excluded all CNVs of less than 100kb and all CNVs made 
with less than 10 consecutive markers. We excluded samples with more than a total of 20 
CNVs, as such samples are more likely to contain artefactual calls. We excluded calls that 
fell within 500kb of the centromere or telomere of each chromosome and any calls falling 
within immunoglobulin regions. We excluded calls occurring in more than 1% of our 
control sample, and calls made over regions of the genome where the marker density was 
low (<1 marker per 200,000bp (n=134)).
As an additional level of assurance that our results were not biased by poorly performing 
samples clustering in particular cohorts, we removed the worst performing 10% of samples 
as defined by the LRRSD and BAFSD across all cohorts and re-analysed our data. This 
tightened our thresholds for inclusion of a sample in this analysis to a LRRSD of 0.2241, a 
BAFSD of 0.0390 and a genotype call rate of greater than 99%.
STATISTICAL ANALYSIS
To test for statistical significance and effect sizes we calculated odds ratios, Pearson’s chi-
square or Fisher’s exact statistic for the frequency of samples with CNVs in cases and 
controls. We estimated the proportion of genetic risk for depression contributed to by our 
results by performing a logistic regression analysis and calculating pseudo R2. All statistical 
calculations were performed in STATA IC v10.1 (24) or PLINK v1.07 (25). Graphs were 
created using STATA IC v10.1 and Microsoft Excel (2011).
Further information on methods and analysis can be found in the supplementary 
information.
RESULTS
2,723 cases of recurrent depression, 348 screened controls and 4,828 unscreened controls 
passed quality control and were used in our main analysis. Overall, the proportion of 
samples with a CNV was increased in cases when compared to screened controls and 
WTCCC2 controls (p=0.019, OR=1.31 (95% CI 1.04 - 1.64) and p=0.025, OR=1.11 (95% 
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CI 1.01 - 1.23) respectively). After stratifying by type of CNV, deletions accounted for this 
change in both cohorts (p=5.6×10−4, OR=1.52 (95% CI 1.20 - 1.93) and p=7.7×10−6, OR 
=1.25 (95% CI 1.13 - 1.37) respectively). Table 1 illustrates the frequency of samples with a 
CNV, stratified into deletions and duplications, in screened controls, WTCCC2 controls, and 
cases. Fig 1 illustrates the proportion of samples with a CNV, stratified by type of CNV, 
across cohorts.
We then stratified our dataset into samples containing CNVs covering gene coding (genic) 
regions and non-gene coding (intergenic) regions, as defined by RefSeq gene annotation 
coordinates available from the UCSC genome browser (http://genome.ucsc.edu/). The 
frequency of samples with deletion CNVs in gene coding regions was significantly 
increased in cases when compared to screened controls and WTCCC2 controls (p=4.2×10−5, 
OR 1.78 (95% CI 1.35 - 2.35) and p=7.2×10−6, OR 1.27 (95% CI 1.14 - 1.41) respectively). 
We further divided the samples with gene coding deletion CNVs into those with deletions 
interrupting exons and those with only intronic deletions. We found an increased frequency 
of cases with an exonic deletion CNV when compared to screened controls and WTCCC2 
controls (p=1.70×10−5, OR 1.87 (95% CI 1.40 - 2.49) and p=1.04×10−5, OR 1.27 (95% CI 
1.14 - 1.41) respectively). Intronic deletions were not associated (p=1.00, OR 1.00 (95% CI 
0.38 - 2.60) and p=0.58, OR 0.91 (95% CI 0.66 - 1.24) respectively) however low numbers 
of samples with only intronic CNVs reduced our power to detect an effect. Table 2 details 
results from this analysis and Fig. 2 illustrates the frequency of samples with exonic and 
intronic deletions, across cohorts. Tables S1a and S1b in the supplementary information 
detail all results for all regions, whilst Fig S1a contrasts the results for deletion CNVs shown 
in Fig 2 with the results for duplication CNVs. Further details on absolute numbers of 
CNVs, number of CNVs per sample, and mean and median CNV size can be found in table 
S1k in the supplementary information. Within an analysis for CNVs that occur only once in 
the dataset (singleton CNVs) we found a broadly similar enrichment within our cases when 
compared to the WTCCC2 control cohort (1 sided empirical p value = 0.0054). Further 
details of this analysis can be found in the supplementary information.
Analyses such as ours can be affected by differences in sample quality between groups, and 
also by population stratification. We attempted to account for this by performing analyses, 
post hoc, excluding the worst performing samples across our data set and restricted to a UK-
only sample set. The association between deletion CNVs occurring across the whole 
genome, gene coding regions and exons remains significant in both analyses. Full details of 
these analyses are contained in pages 6-15 the supplementary information.
Given the differences indicated in Figs 1 & 2 between the screened control cohort and the 
WTCCC2 control cohort we further analysed these two cohorts for significant differences, 
again stratifying by type of CNV made over A) genic and intergenic areas and B) exonic and 
intronic areas. There were no significant differences for the frequency of samples with 
CNVs throughout the genome between screened controls and WTCCC2 controls, although 
there was a trend for deletion CNVs (p=0.096, OR 1.22 (95% CI 0.97 - 1.54)). However, in 
the analysis stratified into genic/intergenic and exonic/intronic CNVs, significantly more 
deletion CNVs were seen in the WTCCC2 group than the screened control group in genic 
regions and exons (p=0.016, OR 1.40 (95% CI 1.06 - 1.84); p=0.0074, OR 1.47 (95% CI 
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1.11 - 1.95) respectively) but not in intergenic and intronic regions (p=0.79, OR 1.04 (95% 
CI 0.78 - 1.39) and p=1.00, OR 1.06 (95% CI 0.52 - 2.15) respectively. Again, low numbers 
of samples with only intronic CNVs reduced our power to detect an effect. No significant 
differences were seen in duplication CNV frequency. Results are presented in table S1g in 
the online supplementary information.
The WTCCC2 cohort is comprised of the 1958 British birth cohort and the national blood 
service cohort. As these represent samples drawn from different populations we performed 
an additional analysis comparing the frequency of samples with CNVs between these two 
subsets. More detail on this, details on stratification of our results by gender, and other 
information can be found in pages 18-22 of the supplementary information.
CNVs in various regions of the genome have previously been associated with psychiatric 
disorders such as schizophrenia (26). We performed an analysis across regions previously 
implicated in schizophrenia and a more detailed analysis of regions 1q21.1, 15q13.3 and 
22q11.2 (13, 14, 16). We found that our cases were significantly enriched with CNVs in 
regions previously implicated in schizophrenia when compared to screened controls and 
when both deletions and duplications were considered together (p=0.0190, OR=3.21 
(95%CI 1.07 - 9.68)). However no significant difference was observed when cases were 
compared to the WTCCC2 controls. We observed no significant differences in CNV 
frequency in the 1q21.1 region. We saw a nominally reduced frequency of cases with 
deletion or duplication CNVs in 15q13.3 compared to the national blood service subset of 
the WTCCC2 sample (p=0.044). We saw a nominally increased frequency of samples with 
deletion CNVs in 22q11.2 in our case sample when compared to the national blood service 
subset of the WTCCC2 control sample (p=0.045). Full details, including tables of 
frequencies for all regions and UCSC browser illustrations and individual CNV plots for 
regions 1q21.1, 15q13.3 and 22q11.2, can be found in pages 25-33 of the supplementary 
information.
DISCUSSION
This is the largest analysis of CNVs in recurrent depression performed to date. The results of 
our analysis suggest that rare deletion CNVs over 100Kb in size are significantly enriched in 
cases of recurrent depression. Furthermore, genic and exonic deletion CNVs show the 
greatest enrichment in our sample. We see a continuum of increasing deletion CNV 
frequency throughout our cohorts with the lowest frequency in screened controls, raised in 
unscreened controls and highest in cases. The only other study of CNVs in depressive 
disorder thus far focussed on individual variants rather than results from across the genome 
(27).
There is some weight to the hypothesis that cases of recurrent depression will be associated 
with CNVs. Other studies have found that deletion CNVs, and to a lesser extent duplication 
CNVs, are also associated with psychiatric disorders such as autism, schizophrenia and 
ADHD (see, for example (11, 12, 15)). Furthermore, other research suggests that similar 
CNVs can predispose to a variety of neurological and psychiatric disorders (10). Other 
studies of CNVs in affective disorders have concentrated on bipolar disorder (28, 29). These 
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studies do not find an association of CNVs with cases. Recurrent depression and bipolar 
disorder are overlapping but distinct disorders, so both results may be correct. In general the 
literature on CNVs in psychiatric disorders (especially autism and schizophrenia) supports 
the involvement of CNVs in specific areas of the genome, although the absolute numbers at 
each locus are low, and large sample sizes are needed to provide statistically significant 
evidence of association. Within table S2a in the supplementary information we present 
counts of CNVs in areas of the genome previously associated with schizophrenia. Whilst we 
find a significant difference when the total number of cases with CNVs in these areas is 
compared with the total number of screened controls with CNVs in these areas, no 
comparisons within individual areas are significant. However some areas warrant further 
research. For example, we see two and three cases respectively with the microdeletion and 
microduplication of 16p11.2 that has previously been associated with autism and 
schizophrenia respectively (30, 31). 2 out of 3 cases with the 16p11.2 duplication, but 
neither of the cases with the deletion, also had mood congruent psychotic symptoms. One 
case has the large 22q11.2 microdeletion associated with numerous clinical syndromes (as 
well as schizophrenia) (32). Exonic deletions in neurexin 1 have also been suggested to play 
a role in schizophrenia (33, 34). We see two cases with microdeletions affecting neurexin 1 
in our cohort and 1 case with a deletion immediately downstream of the gene. 4 WTCCC2 
controls have neurexin 1 deletions, and a further 2 have deletions immediately downstream 
of the gene. No screened controls have deletions of neurexin 1 within or downstream of the 
gene. Our data provides evidence for the presence of specific CNVs in some regions of the 
genome previously implicated in other psychiatric disorders in a minority of our cases.
In 1967 Gottesman and Shields commented that psychiatric disorders may represent the 
extremes of more general continuums of normal psychosocial functioning (35). They 
highlighted that this implied that the genetic aetiology of psychiatric disorders was likely to 
be highly complex. Modern research in psychiatric genetics indicates that this model may be 
applicable, and its renaissance is gathering momentum (25, 36). Perhaps those with a low 
number of deleterious CNVs, particularly deletions, are more likely to undergo development 
in a manner that fosters emotionally and cognitively adaptive behaviours associated with 
higher resilience to developing psychiatric disorders, such as recurrent depression. Such a 
theory may be applicable to other complex disorders in medicine, however it does suggest 
that the genetic aetiology of complex diseases will involve multiple genes, each with 
multiple biological effects, each subject to gene-gene interactions, and the entire milieu 
subject to environmental modification over the lifespan of the organism. Particular patterns 
of genetic variation and environmental interaction may be more strongly associated with 
complex disease than specific genes per se.
We performed a logistic regression analysis on our data (details in methods and 
supplementary information) which indicated that 0.87% (pseudo R2, Nagelkerke method, 
table S3g in the supplementary information) of the variance between RDD cases and 
screened controls is explained by our results. Although not explaining a large proportion, 
this is nonetheless a significant finding in a study of the genetic architecture of a complex 
disorder and underlines the genetic complexity of disorders such as recurrent depression. 
Only a limited number of large CNV events can be reliably detected using microarrays such 
as the Illumina Beadarray used in our experiment, and what we observe may extend to rare 
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variants in general. In the near future more detailed studies, such as those involving large 
scale whole genome sequencing efforts, may uncover more rare variants than are currently 
detectable. This information will then allow us to make a better assessment of the role of 
rare variants in recurrent depression and psychiatric disorders in general.
Recurrent depression represents an increasingly prominent health problem, especially in 
developed countries. It conspicuously lacks any clinically useful biomarkers to guide 
diagnosis or treatment, which often proceeds on a trial-and-error basis and frequently does 
not lead to sustained remission. Elucidating the genetic architecture of diseases like 
recurrent depression has the potential to, in collaboration with other avenues of research, 
inform both diagnosis and treatment and our results thus represent a significant step towards 
identifying the biological underpinnings of a complex and hitherto genetically obscure 
psychiatric disorder.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Proportion of samples with deletion and duplication CNVs across cohorts.
Error bars represent 95% confidence intervals.
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Fig 2. Proportion of samples with exonic and intronic deletion CNVs across cohorts.
Error bars represent 95% confidence intervals.
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Table 1
Frequency of samples with CNVs stratified by type, in screened controls, WTCCC2 
controls and cases.
Screened Controls
(N=348)
WTCCC2 Controls
(N=4828)
Cases
(N=2723)
No. samples with a deletion 11031.6%
1740
36.0%
1123
41.2%
No. samples with a duplication 13237.9%
1823
37.8%
1047
38.5%
No. samples with a deletion or a duplication 19856.9%
2932
60.7%
1725
63.3%
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Table 2
Frequency of samples with gene coding deletion CNVs stratified into exonic, intronic, 
genic and intergenic regions, in screened controls, WTCCC2 controls and cases.
Screened Controls
(N=348)
WTCCC2 Controls
(N=4828)
Cases
(N=2723)
No. samples with an exonic deletion*
61
17.5%
1150
23.8%
774
28.4%
No. samples with an intronic deletion **
8
2.3%
117
2.4%
60
2.2%
No. samples with a genic deletion 6719.2%
1208
25.0%
811
29.8%
No. samples with an intergenic deletion 5917.0%
846
17.5%
523
19.2%
*
Refers to samples with deletions with any exonic coverage
**
Refers to samples with deletions with only intronic coverage
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